Core Viewpoint - US equities experienced minimal changes following President Trump's announcement of a global tariff increase to 15% after a Supreme Court ruling invalidated his previous tariff framework [1] Group 1: Market Reaction - The S&P 500 index remained around the flatline during the trading session [1] - The Dow Jones Industrial Average and the Nasdaq Composite also showed minimal movement [1]

Core Viewpoint - The Supreme Court has invalidated President Donald Trump's extensive global tariffs, representing a significant setback for his economic agenda [1] Group 1 - The ruling impacts the administration's trade policy, which was a central element of its economic strategy [1] - The decision may lead to changes in international trade relations and affect various industries reliant on imports and exports [1]

Core Viewpoint - Agilent Technologies, Inc. is a prominent player in the laboratory instruments and services market, with a market capitalization of $35.8 billion, but its stock has underperformed compared to broader market indices over the past year [1][2]. Financial Performance - Agilent's stock has declined by 7.9% over the past 52 weeks and 7.2% year-to-date, while the S&P 500 Index has gained 11.7% during the same period [2]. - The stock has also lagged behind the State Street Health Care Select Sector SPDR ETF, which has seen a 7.4% increase over the past year [3]. Market Sentiment - The stock has faced downward pressure in 2026 due to weak sentiment and profit-taking, despite stable fundamentals and a positive long-term outlook [5]. - Concerns in the market are attributed to ongoing global tariffs and supply chain issues [5]. Earnings Outlook - For the full fiscal year 2026, analysts project an EPS of $5.93, reflecting a 6.1% year-over-year increase [6]. - Agilent has a history of meeting or surpassing earnings expectations, having done so in each of the past four quarters [6]. Analyst Ratings - Among 18 analysts covering Agilent, the consensus rating is a "Moderate Buy," with 12 "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [6]. - The current analyst configuration is more bullish than three months ago, when there were only nine "Strong Buy" ratings [7]. Price Targets - HSBC recently initiated coverage on Agilent with a "Buy" rating and a price target of $180 [7]. - The mean price target for Agilent is $171.25, indicating a 35.5% premium to current price levels, while the highest target of $185 suggests a potential upside of 46.4% [7].

Military equipment will be bought at whatever price. It’s a non-negotiable spend for any regime. That’s why North Korea spends 25%+ of its GDP on the military.So it’s not totally crazy to reboot manufacturing with a military-first approach. It may work over the very long run. The issue is that those armaments need to be price-competitive abroad to win any war of attrition abroad.For example, if their drones cost $2000 and your missiles cost $2M, that can only be sustained so long as the money printer keeps ...